Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Northfield Suffers Setback On Phase III PolyHeme Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Data discrepancies, protocol violations mar preliminary top-line results for experimental blood substitute.

You may also be interested in...



Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study

“Exceeding the noninferiority endpoint by a small margin” in the study should not keep the product out of the broad emergency trauma setting, CEO Gould tells “The Pink Sheet” DAILY.

Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study

“Exceeding the noninferiority endpoint by a small margin” in the study should not keep the product out of the broad emergency trauma setting, CEO Gould tells “The Pink Sheet” DAILY.

U.S. Navy Plans To Proceed With Hemopure Development

Following negative review by FDA advisory committee, Navy will work on a revised clinical trial protocol for a scaled-down Phase II study.

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel